Miguel Munoz, MD
Endocrinology, Diabetes & Metabolism · Marietta, GANPI 1770629230
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $429,910 of the $475,799 with a category attached, or 90.4%. Lilly USA, LLC accounts for 63.7% of it on its own, with 53 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,621 payments — averaging $293.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$303K
- Novo Nordisk$128K
- Sanofi-aventis U.S. LLC$17K
- Tandem Diabetes Care, Inc.$8K
- AstraZeneca$7K
- Dexcom, Inc.$3K
- plus $10K from 48 others
What the payments were for
- Consulting fees$4,2251%
- Speaking & faculty fees$429,91090%
- Travel & lodging$18,1634%
- Food & beverage$23,0825%
- Education$4180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$126,414
- TRULICITY$81,351
- RYBELSUS$54,716
- Ozempic$53,371
- BAQSIMI$16,950
- SOLIQUA 100/33$10,196
- t:slim X2 Insulin Pump with Control-IQ$7,242
- FARXIGA$6,800
- TOUJEO$5,161
- DEXCOM CGM$2,304
- NP Thyroid 60$1,185
- Tresiba$754
- Omnipod$135
- InPen$127
- Kerendia$122
How this compares
$475,799 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 413 | $577,687 |
| OzempicSemaglutide | 235 | $399,965 |
| FarxigaDapagliflozin Propanediol | 104 | $150,746 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 106 | $146,386 |
| JardianceEmpagliflozin | 104 | $135,102 |
| TymlosAbaloparatide | 43 | $112,275 |
| TrulicityDulaglutide | 64 | $93,032 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $84,438 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $60,836 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $33,993 |
| JanuviaSitagliptin Phosphate | 29 | $33,884 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $32,727 |
| GenotropinSomatropin | 16 | $32,575 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $32,142 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 16 | $29,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $302,889 | $670,719477 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $127,927 | $546,351341 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $405 | $169,095128 claims |
| AstraZenecaFarxiga | $7,489 | $150,746104 claims |
| Radius Health, Inc.Tymlos | $315 | $112,27543 claims |
| PfizerGenotropin, Levoxyl | $141 | $34,50976 claims |
| MerckJanuvia | $235 | $33,88429 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $16,592 | $32,14228 claims |
| AbbVieSynthroid | $313 | $14,400131 claims |
| IBSA Pharma Inc.Tirosint | $441 | $4,27114 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $274 | $3,393362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Marietta
- Jean MolinaryMarietta$8K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
- Naland ShenoySnellville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.